Year: 2023

BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the third quarter ended September 30, 2023 and providing corporate updates on Thursday, November 9, 2023. The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-877-451-6152 from the United States or 1-201-389-0879 internationally, followed by the conference ID: 13741400. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Following the completion of the call, a webcast replay will be available on the website. About X4 Pharmaceuticals X4 Pharmaceuticals...

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) — Virtu Financial, Inc. (NASDAQ: VIRT), a leading provider of financial services and products that leverages cutting edge technology to deliver innovative, transparent trading solutions to its clients and liquidity to the global markets, today reported results for the third quarter ended September 30, 2023. Third Quarter 2023:Net income of $117.6 million; Normalized Adjusted Net Income1 of $74.7 million Basic and diluted earnings per share of $0.63; Normalized Adjusted EPS1 of $0.45 Total revenues of $630.2 million; Trading income, net, of $316.1 million; Net income Margin of 18.7%2Adjusted Net Trading Income1 of $298.0 millionAdjusted EBITDA1 of $139.5 million; Adjusted EBITDA Margin1 of 46.8% Share buybacks of $48.8 million, or 2.7 million shares, under the Share Repurchase Program3The...

– Q3 2023 ORLADEYO net revenue of $85.7 million (+29.8 percent y-o-y) — – Company expects to achieve no less than $320 million in full year 2023 ORLADEYO revenue and $1 billion in peak ORLADEYO revenue – – Net cash utilization of $16.5 million in Q3 2023 (-43.9 percent y-o-y) – – Company to host R&D Day on Friday, November 3rd to introduce additional therapies from its pipeline – RESEARCH TRIANGLE PARK, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update. “With nearly three years of launch data, we have excellent visibility into the pattern of growth for ORLADEYO and we remain on track to achieve the no less than $320 million in ORLADEYO...

– Net Sales Increased by 16% Year-over-Year –– GAAP & Non-GAAP EPS Increased 31% and 29% Respectively, Year-over-Year –– Automotive Sales Increased by 31% Year-over-Year Led by E-Mobility – MANCHESTER, N.H., Nov. 02, 2023 (GLOBE NEWSWIRE) — Allegro MicroSystems, Inc. (“Allegro” or the “Company”) (Nasdaq:ALGM), a global leader in power and sensing semiconductor solutions for motion control and energy efficient systems, today announced financial results for its second quarter which ended September 29, 2023. “We delivered second quarter net sales of $276 million dollars, up 16% year-over-year, driven by continued strength in Automotive, which grew 31% year-over-year. We also achieved record non-GAAP Diluted Earnings per Share of $0.40, an increase of 29% year-over-year,” said Vineet Nargolwala, President and CEO of Allegro MicroSystems....